With FDA Clinical Hold Lifted, Idenix Hopes To Combine Its “Nuc” With A Protease Inhibitor For HCV
This article was originally published in The Pink Sheet Daily
Idenix’s IDX184 is the only unpartnered nucleoside polymerase inhibitor for hepatitis C in clinical development. With an FDA hold lifted, the company wants to make quick progress testing ‘184 in interferon-free regimens for HCV.
You may also be interested in...
The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.